Skip to main content

Table 1 Baseline characteristics of patients

From: Safety, tolerability and immunogenicity of V934/V935 hTERT vaccination in cancer patients with selected solid tumors: a phase I study

Patients in population37100
Age (years)
 Patients with data37 
Racial origin
Baseline ECOG
Primary malignancies
 Bladder carcinoma12.7
 Breast cancer38.1
 Gastroesophageal junction12.7
 Malignant melanoma38.1
 Non-small-cell lung cancer821.6
 Pancreatic carcinoma12.7
 Prostate cancer1437.8
 Renal cell carcinoma12.7
  1. Subjects with missing baseline information are excluded from the corresponding analysis
  2. SD standard deviation